top of page

Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy to boost progranulin levels in the brain

  • Jul 10, 2024
  • 1 min read

CEO William Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients treated, and previews an upcoming conference in September.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page